Bedfont® proudly announces the successful transformation of unused space into a Wellbeing Garden.
‘Very Clear Signal’ That Survival Improved With Addition of Durvalumab in SCLC
The phase III ADRIATIC trial showed that adding consolidation treatment with durvalumab (Imfinzi) after concurrent chemoradiotherapy significantly improved progression-free and overall survival in patients with